Skip to main content
Clinical Trials/JPRN-C000000051
JPRN-C000000051CompletedPhase 1

A phase I/II study of hepatic arterial 5-flurouracil (5FU) combined with intravenous irinotecan hydrochloride (CPT-11) for metastatic colorectal cancer isolated in the liver. (JCOG 0208-DI) - A phase I/II study of hepatic arterial 5FU combined with intravenous CPT-11 for metastatic colorectal cancer isolated in the liver. (JCOG 0208-DI)

Japan Clinical Oncology Group(JCOG)0 sites30 target enrollmentStarted: August 8, 2005Last updated:
Conditions

Trial Snapshot

Phase
Phase 1
Status
Completed
Sponsor
Enrollment
30

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
20years-old to 70years-old (—)
Sex
All

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1) Massive pleural effusion or massive ascites. 2) Active bleeding from digestive organ. 3) Active infection. 4) Watery diarrhea. 5) Other uncontrolled severe illness. 6) Active other malignancy. 7) Prior radiation therapy for abdomen. 8) Positive hepatitis-B antigen or anti-hepatitis-C antibody. 9) Allergy to iodine contrast medium resulting in preclusion of angiography. 10) Severe mental disorder. 11) Pregnant or nursing. 12) Prior placement of hepatic arterial catheter and port system.

Investigators

Sponsor
Japan Clinical Oncology Group(JCOG)

Similar Trials